Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1969 2
1970 2
1971 1
1972 1
1973 1
1974 1
1975 3
1976 2
1977 1
1978 1
1979 4
1980 2
1981 1
1982 2
1983 3
1984 1
1985 4
1986 1
1987 3
1988 1
1989 2
1991 2
1992 1
1993 9
1994 8
1995 7
1996 8
1997 4
1998 3
1999 6
2000 5
2001 8
2002 8
2003 9
2004 6
2005 12
2006 8
2007 9
2008 11
2009 22
2010 14
2011 24
2012 15
2013 16
2014 25
2015 19
2016 20
2017 21
2018 17
2019 20
2020 27
2021 28
2022 29
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

426 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Macroglobulinemia, Waldenstrom, 1"
Page 1
Managing Waldenstrom's macroglobulinemia with BTK inhibitors.
Buske C, Jurczak W, Salem JE, Dimopoulos MA. Buske C, et al. Leukemia. 2023 Jan;37(1):35-46. doi: 10.1038/s41375-022-01732-9. Epub 2022 Nov 19. Leukemia. 2023. PMID: 36402930 Free PMC article. Review.
Bruton's tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT). ...
Bruton's tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenstrom's ma …
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. Tam CS, et al. Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. Blood. 2020. PMID: 32731259 Free PMC article. Clinical Trial.
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenstrom macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highl …
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenstrom macroglobulinemia (WM …
Venetoclax in Previously Treated Waldenstrom Macroglobulinemia.
Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP. Castillo JJ, et al. J Clin Oncol. 2022 Jan 1;40(1):63-71. doi: 10.1200/JCO.21.01194. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793256 Free PMC article. Clinical Trial.
PURPOSE: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenstrom macroglobulinemia (WM). Venetoclax is a potent BCL2 antagonist and triggers in vitro apoptosis of WM cells. ...All patients were MYD88 L265P-mutated, …
PURPOSE: BCL2 is overexpressed and confers prosurvival signaling in malignant lymphoplasmacytic cells in Waldenstrom macroglobulin …
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Kyle RA, et al. Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Leukemia. 2010. PMID: 20410922 Free PMC article. Review.
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproli …
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years …
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM. Röth A, et al. Blood. 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. Blood. 2022. PMID: 35687757 Free PMC article. Clinical Trial.
Forty-two patients with screening hemoglobin 10 g/dL, elevated bilirubin, and 1 CAD symptom received sutimlimab (n = 22) or placebo (n = 20) on days 0 and 7 and then biweekly. ...Sutimlimab, but not placebo, significantly increased mean hemoglobin and FACIT-Fatigue scores …
Forty-two patients with screening hemoglobin 10 g/dL, elevated bilirubin, and 1 CAD symptom received sutimlimab (n = 22) or placebo ( …
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS. Dimopoulos MA, et al. J Clin Oncol. 2023 Nov 20;41(33):5099-5106. doi: 10.1200/JCO.22.02830. Epub 2023 Jul 21. J Clin Oncol. 2023. PMID: 37478390 Clinical Trial.
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN. ...At 44.4-month median follow-up, VGPR …
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Wald …
Ibrutinib in previously treated Waldenstrom's macroglobulinemia.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Treon SP, et al. N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548. N Engl J Med. 2015. PMID: 25853747 Free article. Clinical Trial.
BACKGROUND: MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenstrom's macroglobulinemia. MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib. ...CONCLUSIONS: Ibrutinib was highly active, associated with …
BACKGROUND: MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenstrom's macroglobulinemia. MYD88(L265P) trigg …
Waldenstrom macroglobulinemia.
Kasi PM, Ansell SM, Gertz MA. Kasi PM, et al. Clin Adv Hematol Oncol. 2015 Jan;13(1):56-66. Clin Adv Hematol Oncol. 2015. PMID: 25679974 Review.
Waldenstrom macroglobulinemia (WM) is an indolent low-grade lymphoma characterized by bone marrow infiltration with lymphoplasmacytic cells associated with a monoclonal immunoglobulin M protein. ...A treatment algorithm based on Mayo Stratification for Macroglobu …
Waldenstrom macroglobulinemia (WM) is an indolent low-grade lymphoma characterized by bone marrow infiltration with lymphoplas …
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Durie BGM, et al. Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8. Blood Cancer J. 2020. PMID: 32393732 Free PMC article. Clinical Trial.
Both PFS and OS were improved with VRd versus Rd adjusting for age (P-values: 0.013 [PFS]; 0.033 [OS])). Median duration of Rd maintenance was 17.1 months. The addition of bortezomib to lenalidomide dexamethasone for induction therapy results in a statistically significant …
Both PFS and OS were improved with VRd versus Rd adjusting for age (P-values: 0.013 [PFS]; 0.033 [OS])). Median duration of Rd maintenance w …
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
BACKGROUND: Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenstrom's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab in patients with this disease, both in those who had …
BACKGROUND: Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenstrom's macroglobulinemia, a …
426 results